Abstract
Elderly patients with small cell lung cancer derive a statistically significant benefit from the administration of combination chemotherapy. Numerous clinical trials have demonstrated high response rates and impressive median survivals with carboplatin and etoposide, cisplatin and etoposide, and other regimens. All elderly patients with small cell lung cancer should be evaluated by a medical oncologist to determine whether they are candidates for chemotherapy.
Keywords:
chemotherapy; clinical trials; elderly; lung cancer; radiation; small cell lung cancer; survival.
MeSH terms
-
Age of Onset
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Small Cell / drug therapy*
-
Carcinoma, Small Cell / epidemiology
-
Carcinoma, Small Cell / pathology
-
Carcinoma, Small Cell / therapy
-
Chemoradiotherapy
-
Comorbidity
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / epidemiology
-
Lung Neoplasms / pathology
-
Lung Neoplasms / therapy
-
Neoplasm Staging
-
Proportional Hazards Models
-
Prospective Studies
-
Retrospective Studies
-
Survival Analysis
-
Treatment Outcome